Asciminib

Therapeutic indications

Asciminib is indicated for:

Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP)

Irrespective of gender only Adults (18 years old or older)

Asciminib is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 80 mg in 2 divided doses daily

Contraindications

Active ingredient Asciminib is contraindicated in the following cases:

Lactation

It is unknown whether asciminib/metabolites are excreted in human milk. There are no data on the effects of asciminib on the breast-fed newborn/infant or on milk production. Because of the potential for serious adverse reactions in the breast-fed newborn/infant, breast-feeding should be discontinued during treatment and for at least 3 days after stopping treatment with asciminib.

Medication Recommendation

Receive personalized medication regimen for every patient case

Ask the Reasoner

Related medicines